HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $15 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.0%

Neg 0% Neu 90% Pos 0%

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:ACTU) with a Buy and maintains $15 price target.